Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.
Oxid Med Cell Longev. 2017;2017:1864578. doi: 10.1155/2017/1864578. Epub 2017 Dec 19.
Oxid Med Cell Longev. 2017.
PMID: 29410730
Free PMC article.
NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.
Khalil HS, Langdon SP, Kankia IH, Bown J, Deeni YY.
Khalil HS, et al. Among authors: kankia ih.
Oxid Med Cell Longev. 2016;2016:4148791. doi: 10.1155/2016/4148791. Epub 2015 Dec 7.
Oxid Med Cell Longev. 2016.
PMID: 26770651
Free PMC article.
Item in Clipboard
Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies.
Paramasivan P, Kankia IH, Langdon SP, Deeni YY.
Paramasivan P, et al. Among authors: kankia ih.
Cancer Drug Resist. 2019 Sep 19;2(3):490-515. doi: 10.20517/cdr.2019.57. eCollection 2019.
Cancer Drug Resist. 2019.
PMID: 35582567
Free PMC article.
Review.
Item in Clipboard
Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors.
Kankia IH, Paramasivan P, Elcombe M, Langdon SP, Deeni YY.
Kankia IH, et al.
Explor Target Antitumor Ther. 2021;2(2):187-203. doi: 10.37349/etat.2021.00040. Epub 2021 Apr 30.
Explor Target Antitumor Ther. 2021.
PMID: 36046141
Free PMC article.
Item in Clipboard
Cite
Cite